August 31, 2017
Norwegian drugmaker Vistin Pharma turns to metformin, sales in Q2 13% lower
Norwegian pharmaceutical company Vistin Pharma ASA said it had strong demand and stable prices for its metformin products in the…
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
August 31, 2017
Biocartis CEO: MSI testing with Idylla shows great potential
Biocartis Group NV has published two study abstracts about the performance of its new set of biomarkers for microsatellite instability…
August 31, 2017
Santhera cleared for visual impairment treatment Raxone in Israel
Santhera Pharmaceuticals has been cleared in Israel for Raxone (idebenone) for visual impairment in adolescents and older, with Leber’s hereditary optic neuropathy (LHON).
August 30, 2017
Historic moment in cancer treatment for Novartis
US Food and Drug Administration (FDA) has approved Novartis’s Kymriah suspension for intravenous infusion, formerly CTL019, the first chimeric antigen…
August 30, 2017
Positive outlook for STADA’s business development in 2017
Stada’s Executive Board presented sound figures for financial year 2016 and a positive outlook for business development in 2017. Board’s…
August 30, 2017
OptiBiotix profit after tax £3.2M
OptiBiotix has made significant progress in the last six months developing a pipeline of innovative products with a strong scientific and clinical evidence base, said Stephen O’Hara, CEO of OptiBiotix Wednesday in the half year financial report.
August 30, 2017
Amryt Pharma names new strategic licensing and licensing VP
Amryt Pharma, a biopharmaceutical company focused on rare and orphan diseases, has appointed Kieran Rooney, as Vice President of Strategic Alliances and Licensing.
August 29, 2017
Allergan settles with Famy Care over patent litigation
Allergan has reached a settlement regarding its litigation with Famy Care Limited relating to certain Allergan’s United States Patent covering Restasis (Cyclosporine Ophthalmic Emulsion) 0.05%.
August 28, 2017
No anti-inflammatory effect with GeNeuro’s/Servier’s multiple sclerosis drug at 6 months
GeNeuro and Servier on Monday said that GNbAC1, for the treatment of certain multiple sclerosis was well tolerated, without statistical…
August 28, 2017
Sanofi buys US-based Protein Sciences
Sanofi has acquired USA based Protein Sciences, a vaccines biotechnology company located in Meriden, Connecticut. The Federal Trade Commission’s approval…